Sivik Global Healthcare’s Blueprint Medicines BPMC Stock Holding History

Sivik Global Healthcare’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$1.07M	–	52
2021 Q4	$1.07M	Buy	+10,000	New	+$1.05M	0.46%	45
2020 Q1	–	Sell	-18,520	Closed	-$1.48M	–	45
2019 Q4	$1.48M	Sell	18,520 -1,480	-7%	-$111K	0.55%	48
2019 Q3	$1.47M	Sell	20,000 -10,000	-33%	-$864K	0.74%	38
2019 Q2	$2.83M	Buy	30,000 +5,000	+20%	+$413K	0.68%	47
2019 Q1	$2M	Buy	+25,000	New	+$1.85M	0.74%	49
2018 Q4	–	Sell	-35,000	Closed	-$2.73M	–	52
2018 Q3	$2.73M	Buy	+35,000	New	+$2.43M	0.98%	44
2018 Q2	–	Sell	-20,000	Closed	-$1.83M	–	64
2018 Q1	$1.83M	Hold	20,000	–	–	0.86%	50
2017 Q4	$1.51M	Buy	+20,000	New	+$1.41M	0.56%	63

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sivik Global Healthcare's BPMC Position: Q1 2022 in Review

Sivik Global Healthcare sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 10,000 shares — an estimated $1.07M sold.

Sivik Global Healthcare first reported a position in BPMC in Q4 2017 and held it in 8 quarters. The position peaked at $2.83M in Q2 2019. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

Sivik Global Healthcare reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
Sivik Global Healthcare sold 10,000 Blueprint Medicines shares in Q1 2022, an estimated $1.07M.
Sivik Global Healthcare first reported a position in Blueprint Medicines in Q4 2017 and held it in 8 quarters.
Sivik Global Healthcare's Blueprint Medicines position peaked at $2.83M in Q2 2019.
248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Sivik Global Healthcare's 13F filing for Q1 2022, filed 9 May 2022.